288 related articles for article (PubMed ID: 25120481)
1. Amylin and its analogs: a friend or foe for the treatment of Alzheimer's disease?
Qiu WQ; Zhu H
Front Aging Neurosci; 2014; 6():186. PubMed ID: 25120481
[TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease.
Zhu H; Wang X; Wallack M; Li H; Carreras I; Dedeoglu A; Hur JY; Zheng H; Li H; Fine R; Mwamburi M; Sun X; Kowall N; Stern RA; Qiu WQ
Mol Psychiatry; 2015 Feb; 20(2):252-62. PubMed ID: 24614496
[TBL] [Abstract][Full Text] [Related]
3. Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer's disease.
Qiu WQ
Neuroscience; 2017 Jul; 356():44-51. PubMed ID: 28528968
[TBL] [Abstract][Full Text] [Related]
4. Association between amylin and amyloid-β peptides in plasma in the context of apolipoprotein E4 allele.
Qiu WQ; Wallack M; Dean M; Liebson E; Mwamburi M; Zhu H
PLoS One; 2014; 9(2):e88063. PubMed ID: 24520345
[TBL] [Abstract][Full Text] [Related]
5. Amylin receptor ligands reduce the pathological cascade of Alzheimer's disease.
Zhu H; Xue X; Wang E; Wallack M; Na H; Hooker JM; Kowall N; Tao Q; Stein TD; Wolozin B; Qiu WQ
Neuropharmacology; 2017 Jun; 119():170-181. PubMed ID: 28363773
[TBL] [Abstract][Full Text] [Related]
6. The Importance of Understanding Amylin Signaling Mechanisms for Therapeutic Development in the Treatment of Alzheimer's Disease.
Servizi S; Corrigan RR; Casadesus G
Curr Pharm Des; 2020; 26(12):1345-1355. PubMed ID: 32188374
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition.
Adler BL; Yarchoan M; Hwang HM; Louneva N; Blair JA; Palm R; Smith MA; Lee HG; Arnold SE; Casadesus G
Neurobiol Aging; 2014 Apr; 35(4):793-801. PubMed ID: 24239383
[TBL] [Abstract][Full Text] [Related]
8. Effects of Amylin Against Amyloid-β-Induced Tauopathy and Synapse Loss in Primary Neurons.
Gan Q; Yao H; Na H; Ballance H; Tao Q; Leung L; Tian H; Zhu H; Wolozin B; Qiu WQ
J Alzheimers Dis; 2019; 70(4):1025-1040. PubMed ID: 31306122
[TBL] [Abstract][Full Text] [Related]
9. Pramlintide Antagonizes Beta Amyloid (Aβ)- and Human Amylin-Induced Depression of Hippocampal Long-Term Potentiation.
Kimura R; MacTavish D; Yang J; Westaway D; Jhamandas JH
Mol Neurobiol; 2017 Jan; 54(1):748-754. PubMed ID: 26768593
[TBL] [Abstract][Full Text] [Related]
10. Human Amylin: From Pathology to Physiology and Pharmacology.
Ling W; Huang YM; Qiao YC; Zhang XX; Zhao HL
Curr Protein Pept Sci; 2019; 20(9):944-957. PubMed ID: 30919775
[TBL] [Abstract][Full Text] [Related]
11. Amylin Pharmacology in Alzheimer's Disease Pathogenesis and Treatment.
Corrigan RR; Piontkivska H; Casadesus G
Curr Neuropharmacol; 2022; 20(10):1894-1907. PubMed ID: 34852745
[TBL] [Abstract][Full Text] [Related]
12. Amylin at the interface between metabolic and neurodegenerative disorders.
Lutz TA; Meyer U
Front Neurosci; 2015; 9():216. PubMed ID: 26136651
[TBL] [Abstract][Full Text] [Related]
13. An amylin analog used as a challenge test for Alzheimer's disease.
Zhu H; Stern RA; Tao Q; Bourlas A; Essis MD; Chivukula M; Rosenzweig J; Steenkamp D; Xia W; Mercier GA; Tripodis Y; Farlow M; Kowall N; Qiu WQ
Alzheimers Dement (N Y); 2017 Jan; 3(1):33-43. PubMed ID: 28503657
[TBL] [Abstract][Full Text] [Related]
14. Amylin in Alzheimer's disease: Pathological peptide or potential treatment?
Mietlicki-Baase EG
Neuropharmacology; 2018 Jul; 136(Pt B):287-297. PubMed ID: 29233636
[TBL] [Abstract][Full Text] [Related]
15. Bloodborne Pancreatic Amylin, A Therapeutic Target for Alzheimer's Disease.
Despa F
Curr Alzheimer Res; 2023 Feb; ():. PubMed ID: 36803745
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of glucagon secretion.
Young A
Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
[TBL] [Abstract][Full Text] [Related]
17. Type-2 Diabetes, Pancreatic Amylin, and Neuronal Metabolic Remodeling in Alzheimer's Disease.
Leibold N; Bain JR; Despa F
Mol Nutr Food Res; 2023 Jan; ():e2200405. PubMed ID: 36708219
[TBL] [Abstract][Full Text] [Related]
18. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
Chen Z; Zhong C
Prog Neurobiol; 2013 Sep; 108():21-43. PubMed ID: 23850509
[TBL] [Abstract][Full Text] [Related]
19. Amylin Signaling in Diabetes and Alzheimer's Disease: Therapy or Pathology?
Grizzanti J; Corrigan R; Servizi S; Casadesus G
J Neurol Neuromedicine; 2019; 4(1):12-16. PubMed ID: 31511851
[TBL] [Abstract][Full Text] [Related]
20. Amylin Treatment Reduces Neuroinflammation and Ameliorates Abnormal Patterns of Gene Expression in the Cerebral Cortex of an Alzheimer's Disease Mouse Model.
Wang E; Zhu H; Wang X; Gower AC; Wallack M; Blusztajn JK; Kowall N; Qiu WQ
J Alzheimers Dis; 2017; 56(1):47-61. PubMed ID: 27911303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
